within Pharmacolibrary.Drugs.ATC.R;

model R01AD03
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.9e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R01AD03</td></tr><td>route:</td><td>intranasal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dexamethasone is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressant effects. It is used for the treatment of various conditions including allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, and respiratory diseases. Dexamethasone is approved for use and is listed by the WHO as an essential medicine. In the context of the ATC code R01AD03, it is used as a nasal preparation for the treatment of nasal inflammation and allergic rhinitis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after intranasal administration.</p><h4>References</h4><ol><li><p>Ormrod, D, &amp; Goa, KL (1999). Intranasal metoclopramide. <i>Drugs</i> 58(2) 315–324. DOI:<a href=\"https://doi.org/10.2165/00003495-199958020-00012\">10.2165/00003495-199958020-00012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10473023/\">https://pubmed.ncbi.nlm.nih.gov/10473023</a></p></li><li><p>Ruan, H, et al., &amp; Zhang, Y (2024). Sustained-Release Hydrogen-Powered Bilateral Microneedles Integrating CD-MOFs for In Situ Treating Allergic Rhinitis. <i>Advanced healthcare materials</i> 13(22) e2400637–None. DOI:<a href=\"https://doi.org/10.1002/adhm.202400637\">10.1002/adhm.202400637</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38749484/\">https://pubmed.ncbi.nlm.nih.gov/38749484</a></p></li><li><p>Cárdenas, G, et al., &amp; Jung-Cook, H (2022). Pharmacokinetic Study of Intranasal Dexamethasone and Methylprednisolone Compared with Intravenous Administration: Two Open-Label, Single-Dose, Two-Period, Two-Sequence, Cross-Over Study in Healthy Volunteers. <i>Pharmaceutics</i> 15(1) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics15010105\">10.3390/pharmaceutics15010105</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36678735/\">https://pubmed.ncbi.nlm.nih.gov/36678735</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R01AD03;
